Telomerase Transport and Targeting

Information

  • Research Project
  • 7685665
  • ApplicationId
    7685665
  • Core Project Number
    R01CA104676
  • Full Project Number
    3R01CA104676-04S2
  • Serial Number
    104676
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2004 - 20 years ago
  • Project End Date
    5/31/2009 - 15 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    6/1/2008 - 16 years ago
  • Budget End Date
    5/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    4
  • Suffix
    S2
  • Award Notice Date
    9/12/2008 - 15 years ago

Telomerase Transport and Targeting

DESCRIPTION (provided by applicant): Human telomerase, the ribonucleoprotein enzyme that maintains telomeres at chromosome termini, is absent in most normal somatic cells and is present in nearly all cancer cells. Activation of telomerase induces cellular immortalization and is critical for the development and progression of tumors. Thus, inhibition of telomerase activity offers a promising approach for treating nearly all cancers. A better understanding of telomerase is needed to allow rational design of effective inhibitors. In humans, telomerase includes two subunits essential for function: an RNA subunit (human telomerase RNA) and a protein subunit (human telomerase reverse transcriptase). The location and mechanism of assembly of the enzyme complex in cancer cells (which may indicate where and how to target telomerase) is not known. Furthermore, identification of additional essential components of telomerase would provide additional potential targets for inhibition. The major objectives of this proposal are to obtain a detailed understanding of the trafficking and assembly of telomerase in cells, and to develop a class of RNA-based telomerase inhibitors effective at limiting or preventing the growth of cancer cells. In vivo analysis will be performed both in Xenopus oocytes (due to the many technical advantages of the system) and cultured human cells (including primary and cancer cell lines). To address our objectives we have defined the following three specific aims: Aim 1: To investigate the pathway of biogenesis of functional telomerase in vivo Aim 2: To examine the localization and trafficking of key human telomerase components in normal and cancer cells Aim 3: To develop efficacious anti-telomerase ribozymes capable of preventing growth of cancer cells.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    44896
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    393
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NCI:44896\
  • Funding Mechanism
  • Study Section
    CAMP
  • Study Section Name
    Cancer Molecular Pathobiology Study Section
  • Organization Name
    UNIVERSITY OF GEORGIA (UGA)
  • Organization Department
    BIOCHEMISTRY
  • Organization DUNS
  • Organization City
    ATHENS
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    306027411
  • Organization District
    UNITED STATES